CryoLife Inc. (NYSE:CRY) shares fell to a low of $17.73 before closing at $18.08. Intraday shares traded counted 1.15 million, which was -239.79% lower than its 30-day average trading volume of 338.97K. CRY’s previous close was $19.05 while the outstanding shares total 37.39M. The firm has a beta of 1.38. The stock’s Relative Strength Index (RSI) is 35.80, with weekly volatility at 4.96% and ATR at 1.36. The CRY stock’s 52-week price range has touched low of $12.63 and a $33.00 high. The stock traded lower over the last trading session, losing -5.09% on 06/26/20.
Investors have identified the Medical Devices company CryoLife Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $719.04 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
CryoLife Inc. (CRY) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For CRY, the company has in raw cash 63.88 million on their books with 6.6 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 214082000 million total, with 43685000 million as their total liabilities.
CRY were able to record 96000.0 as free cash flow during the third quarter of the year, this saw their quarterly net cash flow reduce by 29.58 million. In cash movements, the company had a total of 2.63 million as operating cash flow.
Potential earnings growth for CryoLife Inc. (CRY)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, CryoLife Inc. recorded a total of 66.43 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -1.62% coming in sequential stages and their sales for the third quarter reducing by -0.02%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 22.26 million trying to sell their products during the last quarter, with the result yielding a gross income of 44.17 million. This allows shareholders to hold on to 37.39M with the revenue now reading -0.18 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (0.02 cents a share).
Having a look at the company’s valuation, the company is expected to record 0.31 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CRY sounds very interesting.
Is the stock of CRY attractive?
In related news, VP, Chief Accounting Officer, Horton Amy sold 3,000 shares of the company’s stock in a transaction that recorded on May 28. The sale was performed at an average price of 23.81, for a total value of 71,415. As the sale deal closes, the Director, McCall Ronald D now sold 1,719 shares of the company’s stock, valued at 39,219. Also, Director, McCall Ronald D sold 4,734 shares of the company’s stock in a deal that was recorded on Feb 24. The shares were price at an average price of 26.05 per share, with a total market value of 123,340. Following this completion of acquisition, the VP, General Counsel, Holloway Jean F now holds 8,458 shares of the company’s stock, valued at 253,744. In the last 6 months, insiders have changed their ownership in shares of company stock by 4.10%.
4 out of 5 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on CryoLife Inc.. 0 analysts has assigned a Sell rating on the CRY stock. The 12-month mean consensus price target for the company’s shares has been set at $26.80.